- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for BindRen has been withdrawn at the request of the marketing authorisation holder.
Product information
Latest procedure affecting product information:
IAIN/0004
26/03/2015
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- BindRen
- Active substance
- colestilan
- International non-proprietary name (INN) or common name
- colestilan
- Therapeutic area (MeSH)
- Hyperphosphatemia
- Anatomical therapeutic chemical (ATC) code
- V03AE
Therapeutic indication
Treatment of hyperphosphataemia in adult patients with chronic kidney disease stage 5 receiving haemodialysis or peritoneal dialysis.
News on BindRen
This page was last updated on